Published in J Natl Cancer Inst on June 16, 1993
The causal relation between human papillomavirus and cervical cancer. J Clin Pathol (2002) 14.73
Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol (1998) 9.43
PCR detection of human papillomavirus: comparison between MY09/MY11 and GP5+/GP6+ primer systems. J Clin Microbiol (1997) 5.76
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol (1995) 4.14
A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst (1994) 3.95
Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol (2003) 3.76
Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol (1995) 3.20
Fourier transform infrared (FTIR) spectral mapping of the cervical transformation zone, and dysplastic squamous epithelium. Gynecol Oncol (2004) 2.75
Cervical cancer: epidemiology, prevention and the role of human papillomavirus infection. CMAJ (2001) 2.56
Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol (1995) 2.46
Interaction of papillomaviruses with the cell surface. J Virol (1994) 2.44
Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol (1997) 2.40
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol (1998) 2.21
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
Genital human papillomavirus infection. Proc Natl Acad Sci U S A (1994) 2.12
Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis (2003) 2.06
Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. J Clin Microbiol (2002) 1.94
Homogeneous amplification of genital human alpha papillomaviruses by PCR using novel broad-spectrum GP5+ and GP6+ primers. J Clin Microbiol (2008) 1.90
High prevalence of human papillomavirus (HPV) infections and high frequency of multiple HPV genotypes in human immunodeficiency virus-infected women in Brazil. J Clin Microbiol (2002) 1.83
A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20,000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev (2011) 1.82
Clinical human papillomavirus detection forecasts cervical cancer risk in women over 18 years of follow-up. J Clin Oncol (2012) 1.78
Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer (2000) 1.73
Comparison of the Digene Hybrid Capture 2 assay and Roche AMPLICOR and LINEAR ARRAY human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J Clin Microbiol (2007) 1.66
Intratype variation in 12 human papillomavirus types: a worldwide perspective. J Virol (1996) 1.65
Nonisotopic detection and typing of human papillomavirus DNA in genital samples by the line blot assay. The Canadian Women's HIV study group. J Clin Microbiol (1999) 1.58
Telomerase activity and human papillomavirus in malignant, premalignant and benign cervical lesions. Br J Cancer (1998) 1.58
Abundance of multiple high-risk human papillomavirus (HPV) infections found in cervical cells analyzed by use of an ultrasensitive HPV genotyping assay. J Clin Microbiol (2009) 1.55
Real-time PCR-based system for simultaneous quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol (2003) 1.52
HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer (2001) 1.52
Accuracy and interlaboratory reliability of human papillomavirus DNA testing by hybrid capture. J Clin Microbiol (1995) 1.48
Covariates of cervical cytokine mRNA expression by real-time PCR in adolescents and young women: effects of Chlamydia trachomatis infection, hormonal contraception, and smoking. J Clin Immunol (2006) 1.48
Comparison of physician- and self-collected genital specimens for detection of human papillomavirus in men. J Clin Microbiol (2006) 1.46
comparison of two commercial assays for detection of human papillomavirus (HPV) in cervical scrape specimens: validation of the Roche AMPLICOR HPV test as a means to screen for HPV genotypes associated with a higher risk of cervical disorders. J Clin Microbiol (2005) 1.44
Comparison of the hybrid capture tube test and PCR for detection of human papillomavirus DNA in cervical specimens. J Clin Microbiol (1997) 1.44
Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. J Clin Microbiol (1997) 1.41
The age-specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: implications for screen-and-treat strategies. Int J Cancer (2011) 1.38
Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer (2005) 1.37
Multiple-type human papillomavirus infection in male anogenital sites: prevalence and associated factors. Cancer Epidemiol Biomarkers Prev (2009) 1.31
Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol (2010) 1.25
Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J Clin Microbiol (2006) 1.24
Comparison between the Hybrid Capture II Test and an SPF1/GP6+ PCR-based assay for detection of human papillomavirus DNA in cervical swab samples. J Clin Microbiol (2006) 1.24
Short fragment polymerase chain reaction reverse hybridization line probe assay to detect and genotype a broad spectrum of human papillomavirus types. Clinical evaluation and follow-up. Am J Pathol (1999) 1.23
Type distribution, viral load and integration status of high-risk human papillomaviruses in pre-stages of cervical cancer (CIN). Br J Cancer (2005) 1.22
Estimation of the incidence of genital warts and the cost of illness in Germany: a cross-sectional study. BMC Infect Dis (2008) 1.20
A papillomavirus E2 phosphorylation mutant exhibits normal transient replication and transcription but is defective in transformation and plasmid retention. J Virol (1997) 1.17
Diagnosis of human papillomavirus infection by dry vaginal swabs in military women. Sex Transm Infect (2001) 1.17
Early detection of cervical carcinomas: finding an overall approach. Dtsch Arztebl Int (2008) 1.16
Age-appropriate use of human papillomavirus vaccines in the U.S. Gynecol Oncol (2009) 1.16
Aetiology, pathogenesis, and pathology of cervical neoplasia. J Clin Pathol (1998) 1.15
Human papillomaviruses and cervical neoplasia. I. Classification, virology, pathology, and epidemiology. J Clin Pathol (1994) 1.15
Results of human papillomavirus DNA testing with the hybrid capture 2 assay are reproducible. J Clin Microbiol (2002) 1.14
An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer (2009) 1.14
Cancer prevention research - then and now. Nat Rev Cancer (2009) 1.12
Effectiveness of a simple rapid human papillomavirus DNA test in rural Nigeria. Int J Cancer (2012) 1.12
Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst (2003) 1.10
Human papillomavirus infection and risk of progression of epithelial abnormalities of the cervix. Br J Cancer (1996) 1.08
Human papillomavirus status in the prediction of high-grade cervical intraepithelial neoplasia in patients with persistent low-grade cervical cytological abnormalities. Br J Cancer (1995) 1.07
Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer (2000) 1.06
Comparison between prototype hybrid capture 3 and hybrid capture 2 human papillomavirus DNA assays for detection of high-grade cervical intraepithelial neoplasia and cancer. J Clin Microbiol (2003) 1.05
HPV 9G DNA chip: 100% clinical sensitivity and specificity. J Clin Microbiol (2011) 1.05
Detection of genital human papillomavirus by single-tube nested PCR and type-specific oligonucleotide hybridization. J Clin Microbiol (1995) 1.02
Epidemiology of genital warts in England and Wales: 1971 to 1994. Genitourin Med (1997) 1.02
Elevated systemic levels of inflammatory cytokines in older women with persistent cervical human papillomavirus infection. Cancer Epidemiol Biomarkers Prev (2010) 1.02
Detection of human papillomavirus DNA in pterygia from different geographical regions. Br J Ophthalmol (2003) 1.01
Prevalence of high-risk human papillomavirus among older women. Obstet Gynecol (2008) 1.01
Genotyping human papillomavirus type 16 isolates from persistently infected promiscuous individuals and cervical neoplasia patients. J Clin Microbiol (1995) 1.01
Perinatal transmission of human papilomavirus DNA. Virol J (2009) 0.99
Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med (1997) 0.99
Ubiquitin-fused and/or multiple early genes from cottontail rabbit papillomavirus as DNA vaccines. J Virol (2002) 0.99
The physical state of HPV16 infection and its clinical significance in cancer precursor lesion and cervical carcinoma. J Cancer Res Clin Oncol (2008) 0.98
Human papillomavirus is not associated with colorectal cancer in a large international study. Cancer Causes Control (2010) 0.98
Lymphoid follicles are generated in high-grade cervical dysplasia and have differing characteristics depending on HIV status. Am J Pathol (2002) 0.97
Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer (2001) 0.97
Thin-layer liquid-based cervical cytology and PCR for detecting and typing human papillomavirus DNA in Flemish women. Br J Cancer (2003) 0.96
Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96
Mortality related to sexually transmitted diseases in US women, 1973 through 1992. Am J Public Health (1997) 0.96
Expression of folate receptors and heterogeneous nuclear ribonucleoprotein E1 in women with human papillomavirus mediated transformation of cervical tissue to cancer. J Clin Pathol (2003) 0.96
Prevalence and risk factors of Human Papillomavirus (HPV) infection in southern Chinese women - a population-based study. PLoS One (2011) 0.96
Impact of improved classification on the association of human papillomavirus with cervical precancer. Am J Epidemiol (2009) 0.95
Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines (2005) 0.95
Infection and cervical neoplasia: facts and fiction. Int J Clin Exp Pathol (2008) 0.94
Yin yang 1 negatively regulates the differentiation-specific E1 promoter of human papillomavirus type 6. J Virol (2000) 0.94
Biomarkers of cervical dysplasia and carcinoma. J Oncol (2011) 0.94
Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan. Br J Cancer (1999) 0.94
HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer (2005) 0.94
Interferon for the treatment of genital warts: a systematic review. BMC Infect Dis (2009) 0.93
Anal cytological abnormalities and anal HPV infection in men with Centers for Disease Control group IV HIV disease. Genitourin Med (1997) 0.92
Human papillomavirus persistence in young unscreened women, a prospective cohort study. PLoS One (2011) 0.92
Chromosomal biomarkers for detection of human papillomavirus associated genomic instability in epithelial cells of cervical cytology specimens. J Mol Diagn (2007) 0.92
Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16. Br J Cancer (1995) 0.92
Comparison of measurements of human papillomavirus persistence for postcolposcopic surveillance for cervical precancerous lesions. Cancer Epidemiol Biomarkers Prev (2010) 0.91
A novel genital human papillomavirus (HPV), HPV type 74, found in immunosuppressed patients. J Clin Microbiol (1996) 0.91
Strategies to prevent preterm birth. Front Immunol (2014) 0.91
Determinants of squamous intraepithelial lesions (SIL) on Pap smear: the role of HPV infection and of HIV-1-induced immunosuppression. DIANAIDS Collaborative Study Group. Eur J Epidemiol (1997) 0.90
Comparison of europium and chromium release assays: cytotoxicity in healthy individuals and patients with cervical carcinoma. Clin Diagn Lab Immunol (1997) 0.90
Polycyclic aromatic hydrocarbon-DNA adducts in cervix of women infected with carcinogenic human papillomavirus types: an immunohistochemistry study. Mutat Res (2007) 0.90
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50
Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol (1992) 7.14
Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis (1994) 7.00
Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med (1999) 6.92
Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol (1986) 6.88
Residential exposure to magnetic fields and acute lymphoblastic leukemia in children. N Engl J Med (1997) 6.72
Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials (2000) 5.37
Migration patterns and breast cancer risk in Asian-American women. J Natl Cancer Inst (1993) 5.07
Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis (1994) 4.89
Does nondifferential misclassification of exposure always bias a true effect toward the null value? Am J Epidemiol (1990) 4.63
Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol (1991) 4.62
Solid cancers after bone marrow transplantation. N Engl J Med (1997) 4.62
HPV DNA testing in cervical cancer screening: results from women in a high-risk province of Costa Rica. JAMA (2000) 4.62
Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei". Am J Surg Pathol (1995) 4.33
Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst (1991) 4.14
Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst (2000) 3.81
Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J Natl Cancer Inst (1996) 3.76
Design and methods of a population-based natural history study of cervical neoplasia in a rural province of Costa Rica: the Guanacaste Project. Rev Panam Salud Publica (1997) 3.67
Subclassification of serous borderline tumors of the ovary into benign and malignant types. A clinicopathologic study of 65 advanced stage cases. Am J Surg Pathol (1996) 3.63
Population-based study of risk of breast cancer in carriers of BRCA2 mutation. Lancet (1998) 3.61
Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medicine--National Cancer Institute Benzene Study Group. J Natl Cancer Inst (1997) 3.61
Human papillomavirus testing by hybrid capture appears to be useful in triaging women with a cytologic diagnosis of atypical squamous cells of undetermined significance. Am J Obstet Gynecol (1995) 3.59
The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer (1985) 3.50
Optimization and testing of mass spectral library search algorithms for compound identification. J Am Soc Mass Spectrom (1994) 3.46
Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA (1999) 3.37
Clinical impact of rapid antimicrobial susceptibility testing of blood culture isolates. Antimicrob Agents Chemother (1982) 3.09
Determination of left ventricular volumes by ultrasound. Circulation (1971) 3.09
Proportion of breast cancer cases in the United States explained by well-established risk factors. J Natl Cancer Inst (1995) 3.03
Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst (1999) 2.98
Limitations of the case-only design for identifying gene-environment interactions. Am J Epidemiol (2001) 2.97
Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Hum Pathol (2000) 2.96
Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer (1996) 2.91
The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Cancer Epidemiol Biomarkers Prev (2001) 2.87
Screening and intervention for intimate partner abuse: practices and attitudes of primary care physicians. JAMA (1999) 2.78
Women's health and human rights in Afghanistan. JAMA (1998) 2.74
The relation of risk factors to the development of atherosclerosis in saphenous-vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med (1984) 2.70
Established breast cancer risk factors by clinically important tumour characteristics. Br J Cancer (2006) 2.68
A H+-gated urea channel: the link between Helicobacter pylori urease and gastric colonization. Science (2000) 2.67
Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer (1999) 2.66
Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood (1999) 2.65
Random digit dialing in selecting a population-based control group. Am J Epidemiol (1984) 2.64
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer (2005) 2.62
The emerging epidemic of melanoma and squamous cell skin cancer. JAMA (1989) 2.61
Generation of type-specific probes for the detection of single-copy human papillomavirus by a novel in situ hybridization method. Mod Pathol (1998) 2.50
Mammographic densities and risk of breast cancer. Cancer (1991) 2.47
Oncogenic association of specific human papillomavirus types with cervical neoplasia. J Natl Cancer Inst (1987) 2.45
Attributable risk: advantages of a broad definition of exposure. Am J Epidemiol (1994) 2.45
Artificial sweeteners and human bladder cancer. Preliminary results. Lancet (1980) 2.42
High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev (2001) 2.38
Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med (1992) 2.34
Association between childhood acute lymphoblastic leukemia and use of electrical appliances during pregnancy and childhood. Epidemiology (1998) 2.33
The APCI1307K allele and cancer risk in a community-based study of Ashkenazi Jews. Nat Genet (1998) 2.32
A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis (2000) 2.24
Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J Clin Microbiol (1998) 2.21
Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis (1995) 2.21
Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood Cohort Study. Cancer Res (1990) 2.21
Comparison of Southern blot hybridization and polymerase chain reaction methods for the detection of human papillomavirus DNA. J Clin Microbiol (1991) 2.19
Fluoridated drinking water and the occurrence of cancer. J Natl Cancer Inst (1976) 2.19
Angiographic embolization of intractable puerperal hematomas. Am J Obstet Gynecol (1989) 2.16
Non-differential misclassification and bias towards the null: a clarification. Occup Environ Med (1995) 2.15
Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst (1987) 2.12
Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev (1997) 2.12
Clear-cell adenocarcinoma of the genital tract in young females. Registry report. N Engl J Med (1972) 2.11
Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 2.11
The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet (1999) 2.03
Geographic variation in mortality from breast cancer among white women in the United States. J Natl Cancer Inst (1995) 2.03
Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types. Am J Clin Pathol (1994) 2.00
Pseudomyxoma peritonei syndrome. Adv Surg (1996) 1.99
The pathology of intermediate trophoblastic tumors and tumor-like lesions. Int J Gynecol Pathol (2001) 1.98
Breaking the silence. Battered women's perspectives on medical care. Arch Fam Med (1996) 1.94
Epithelioid trophoblastic tumor: a neoplasm distinct from choriocarcinoma and placental site trophoblastic tumor simulating carcinoma. Am J Surg Pathol (1998) 1.93